Evotec (EVT.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE0005664809
Evotec financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 796.00 m EUR | 788.00 m EUR |
| Gross profit | 114.00 m EUR | 65.00 m EUR |
| Operating income | -78.92 m EUR | -66.03 m EUR |
| EBIT | -184.00 m EUR | -140.00 m EUR |
| Net income | -196.00 m EUR | -103.00 m EUR |
| Diluted EPS – continuing operations | -1.11 EUR | -0.58 EUR |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Evotec
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
More stocks
- Jiangyin Pivot Automotive Products Co. Ltd. (301181.SZ)
- GDH Supertime Group Co. Ltd. A (001338.SZ)
- Seco SpA (IOT.MI)
- Korea District Heating Corp (071320.KS)
- Northern Data (NB2.DE)
- Administradora Americana de Inversiones S.A. (AAISA.SN)
- Comptech Composites Corp (301591.SZ)
- Longyan Zhuoyue New Energy Co Ltd (688196.SS)
- Wecome Intelligent Manufacturing Co. Ltd. (603070.SS)
- PARK OHIO HOLDINGS CORP (PKOH)
- MFA FINANCIAL, INC. (MFA)
- Hangzhou Shenhao Technology Co Ltd (300853.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.